NCT02872025View on ClinicalTrials.gov

Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 12, 2016

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Carcinoma, Intraductal, Noninfiltrating
Interventions
DRUG

Pembrolizumab

Injected intralesionally

BIOLOGICAL

Intralesional mRNA 2752

Injected intralesionally

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

ModernaTX, Inc.

INDUSTRY

lead

Laura Esserman

OTHER